Donate For Public and Patients Store Search

Go to AAD Home
Welcome!

DW Weekly

Dermatology World Weekly is a brief, concise digest of the latest news, hand-picked by DW’s editorial team with analysis of why it matters to dermatologists.

Each week editors review the landscape of health care news in DermWorld's core areas of practice management, policy, and patient care, and highlight a few stories with links to AAD resources that provide more context and opportunities to act. If you read the news and wonder, "What does this mean for me?" — DermWorld Weekly is for you.

Read the latest issues below. Let us know if you see a story you'd like us to cover at dweditor@aad.org.

2022 issues

May 18 & 25, 2022

May 25, 2022:

  • Placebo regrowth rate in alopecia areata trials

  • DermWorld Insights and Inquiries: The globalization of monkeypox

  • AADA renews calls for iPLEDGE improvements with IPMG, FDA

  • Seeking comments on atopic dermatitis guidelines on topical therapies

  • Ruxolitinib cream for cutaneous lichen planus

May 18, 2022:

  • Abrocitinib efficacy after switching from dupilumab

  • DermWorld Insights and Inquiries: Coming to grips with lymphocytic thrombophilic arteritis

  • DermWorld Young Physician Focus: Protecting dermatologic scope of practice

  • Seeking comments on atopic dermatitis guidelines on topical therapies

  • New gel effective for excessive underarm sweating

May 4 & 11, 2022

May 11, 2022:

  • Sexual dysfunction associated with finasteride use in men with androgenetic alopecia

  • DermWorld Insights and Inquiries: Lagging ahead — LAG-3 checkpoint inhibition for advanced melanoma

  • FDA grants fast track designation for ichthyosis therapy

  • An analysis of popular HS content on TikTok

  • Academy Advisory Board invites members to submit policy resolutions

  • 2022 MIPS EUC, Promoting Interoperability hardship exception applications available

May 4, 2022:

  • Plantar warts: Local hyperthermia vs. cryotherapy

  • DermWorld Insights and Inquiries: Eruptive pseudoangiomatosis is real

  • Intralesional methotrexate vs. triamcinolone acetonide for nail matrix psoriasis

  • Report shows physician pay is on the rise

  • STD surge continues

April 20 & 27, 2022

April 27, 2022:

  • A novel treatment for molluscum contagiosum?

  • DermWorld Insights and Inquiries: Eye-opening news about oxymetazoline

  • Trends in prescribing spironolactone for acne, HS in adolescents

  • Racial biases in medical notes may contribute to health disparities

  • FDA issues warning about skin lightening products

April 20, 2022:

  • Which biologics are most effective for psoriasis?

  • DermWorld Insights and Inquiries: One Toker over the line — Clarifying Toker cell hyperplasia in Zuska disease and its relationship to hidradenitis suppurativa

  • DermWorld Young Physician Focus: Re-examining itch

  • Are specific body sites prone to surgical site infections?

  • COVID-19 public health emergency renewed

  • The non-physician dermatology workforce

April 6 & 13, 2022

April 13, 2022:

  • Is there an association between isotretinoin and adverse neuropsychiatric outcomes?

  • DermWorld Insights and Inquiries: Early recognition of rituximab-induced late onset neutropenia is essential

  • Election winners Dialogues interview

  • Treating seborrheic keratosis with hydrogen peroxide

  • IL-17 blockade reduces psoriatic lesional expression of COVID-19 receptor

April 6, 2022:

  • A comprehensive review of rosacea treatments

  • DermWorld Insights and Inquiries: “Stepping up” to off-label dosing of biologics

  • Improving itch in prurigo nodularis patients

  • What acne treatments are being recommended on YouTube?

  • A review of systemic treatments for vitiligo

March 16, 23 & 30, 2022

March 30, 2022:

  • The rankings are in: Minoxidil, finasteride, and dutasteride for male androgenetic alopecia

  • DermWorld Insights and Inquiries: Bowel-associated dermatosis-arthritis syndrome (BADAS) — The story behind the acronym

  • Acne and insulin resistance

  • Health Care Provider Protection Act becomes law

  • What dermatologists should know about VEXAS syndrome

March 23, 2022:

  • Acitretin: A new therapy for onychomycosis?

  • DermWorld Insights and Inquiries: A new wrinkle in the diagnosis of cystic fibrosis?

  • Injury and litigation in cutaneous laser surgery

  • Switching from oral to subcutaneous methotrexate

  • FDA warns against use of Renuvion/J-Plasma device for certain aesthetic procedures

  • Extension of COVID-19 telehealth waivers

March 16, 2022:

  • Comparing four cSCC staging systems

  • DermWorld Insights and Inquiries: Mind the gap

  • DermWorld Young Physician Focus: Talking points

  • Potassium monitoring in women on spironolactone

  • Using medical cannabis to treat dermatologic conditions

March 2 & 9, 2022

March 9, 2022:

  • Eight misconceptions about photoprotection in skin of color

  • DermWorld Insights and Inquiries: IL-36 and generalized pustular psoriasis — L’chaim!

  • Derm Coding Consult: Novitas revises shave removal coverage policy to include malignant skin lesions

  • Is spironolactone use associated with risk of cancer?

  • MIPS extreme and uncontrollable circumstances applications reopened

March 2, 2022:

  • Biotin beware: Physician, patient knowledge about lab interference

  • DermWorld Insights and Inquiries: The rhythm of RIME

  • Infections in children treated with dupilumab

  • Cutaneous adverse events are associated with increased survival in patients on anti-PD-1, anti-PD-L1 therapy

  • Will biosimilars cut spending for biologic therapy in the U.S.?

Feb. 16 & 23, 2022

Feb. 23, 2022:

  • Frontal fibrosing alopecia: The effects of sunscreens and moisturizers

  • DermWorld Insights and Inquiries: The vexing verruciform xanthoma

  • DermWorld Young Physician Focus: The patient experience — there’s an app for that

  • Red light vs. blue light therapies for acne

  • Diversity in dermatology clinical trials

Feb. 16, 2022:

  • A review of calcipotriol plus 5-fluorouracil for actinic keratosis

  • DermWorld Insights and Inquiries: Vascular Ehlers-Danlos syndrome: From rupture to rapture?

  • Delayed complications for FDA-approved HA dermal fillers

  • What every physician needs to know about the Disabilities Act

  • Safety of tacrolimus for children with AD

Feb. 2 & 9, 2022

Feb. 9, 2022:

  • Tinted sunscreens: A practical guide to counseling patients

  • DermWorld Insights and Inquiries: Lightening the cutaneous and emotional burden of melasma — cysteamine’s role

  • Nemolizumab plus topicals improve AD itch

  • Is there an association between alopecia areata and retinal diseases?

  • Treating Netherton syndrome with dupilumab

Feb. 2, 2022:

  • A high-fiber diet may affect immunotherapy response for melanoma patients

  • DermWorld Insights and Inquiries: An old dog with a new trick — High dose intralesional steroids in hidradenitis suppurativa

  • Derm Coding Consult: CMS announces new Place of Service code for telehealth provided to patients in their homes

  • 2022 physician depression, burnout survey

  • Topical calcineurin inhibitors for pediatric atopic dermatitis

Jan. 19 & 26, 2022

Jan. 26, 2022:

  • Allergens in hand sanitizers

  • DermWorld Insights and Inquiries: Eccrine syringofibroadenoma — Sweating over the details

  • Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice – Part 8

  • New AAD guidelines address comorbidities and atopic dermatitis

  • FDA approves abrocitinib, upadacitinib for atopic dermatitis

  • AMA House of Delegates recap

Jan. 19, 2022:

  • Finasteride: Topical vs. oral for male androgenetic alopecia

  • DermWorld Insights and Inquiries: Probing pityriasis rosea in pregnancy

  • Derm Coding Consult: Dermatology benign, premalignant, and malignant destruction code utilization

  • DermWorld Young Physician Focus: To stress is human

  • Supreme Court upholds CMS vaccine mandate, strikes down OSHA

Jan. 5 & 12, 2022

Jan. 12, 2022:

  • Probiotics for atopic dermatitis?

  • DermWorld Insights and Inquiries: Tarrying for tapinarof

  • Derm Coding Consult: Patch testing unit of service reduction averted

  • Research gap years may impact successful dermatology match

  • Patient satisfaction with live video telehealth declines

Jan. 5, 2022:

  • Cicatricial alopecia following ACD from hair dye

  • DermWorld Insights and Inquiries: Coming full circle (almost) — Low dose oral minoxidil for alopecia

  • FDA approves atopic dermatitis biologic

  • Risk factors for positive surgical margins after excision of MCC

  • Academy Advisory Board invites members to submit policy resolutions

2021 issues

Dec. 8, 15 & 22, 2021

Dec. 22, 2021:

  • Can COVID-19 be transmitted through the skin?

  • DermWorld Insights and Inquiries: Holiday greeting 2021

  • Derm Coding Consult: Anthem updates virtual visit policies

  • No Surprises Act takes effect Jan. 1, 2022

  • An emerging preservative allergen?

Dec. 15, 2021:

  • Female-pattern hair loss: Effect of bicalutamide on minoxidil-induced hypertrichosis

  • DermWorld Insights and Inquiries: Speculating on spicules — Our incomplete knowledge of trichodysplasia spinulosa

  • DermWorld Young Physician Focus: I’m not the enemy

  • Congress addresses impending Medicare cuts

  • Is phototherapy an effective treatment for atopic dermatitis?

Dec. 8, 2021:

  • Factors that may predict chronic spontaneous urticaria recurrence

  • DermWorld Insights and Inquiries: Propranolol and neutrophilic dermatoses — Can beta-blockade be better blockade?

  • Feedback requested: Actinic keratosis clinical guideline update

  • 2021 Annual Report of DataDerm™

  • iPLEDGE deadline approaching

Nov. 17 & Dec. 1, 2021

Dec. 1, 2021:

  • Risk of COVID-19 infection in atopic dermatitis patients

  • DermWorld Insights and Inquiries: The nexus of VEXAS syndrome

  • Skin and gut microbiome in hidradenitis suppurativa

  • Is imiquimod cream effective for keratoacanthomas?

  • Eye care products that may cause patch test reactions

  • CMS, OSHA vaccination deadline approaching

  • Reminder: Check your final 2021 MIPS eligibility status

Nov. 17, 2021:

  • Intralesional acyclovir for cutaneous warts

  • DermWorld Insights and Inquiries: Biotin supplementation for hair and nail health — Does it pass the test?

  • DermWorld Young Physician Focus: Making progress

  • AADA urges iPLEDGE sponsors to delay new platform implementation

  • Pityriasis rubra pilaris-like eruption after mRNA COVID-19 vaccine

  • All individual MIPS clinicians to receive automatic extreme and uncontrollable circumstances exemption

Nov. 3 & 10, 2021

Nov. 10, 2021:

  • CMS, OSHA release rules expanding workforce vaccination requirements

  • DermWorld Insights and Inquiries: Recognizing toxic epidermal necrolysis-like acute cutaneous lupus erythematosus ASAP

  • Prognostic value of lymphovascular invasion in early-stage Merkel cell carcinoma

  • Sunscreen use and blood concentrations of benzene

  • Does exercise influence skin aging, skin health, or androgenetic alopecia?

Nov. 3, 2021:

  • Facial contact dermatitis from cosmetic allergens

  • DermWorld Insights and Inquiries: Humbled again — Alopecic and aseptic nodules of the scalp

  • Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice – Part 7

  • Progression of frontal fibrosing alopecia in Black women

  • What UnitedHealthcare’s Designated Diagnostic Provider program may mean for you: Protect your referral relationship with your dermatopathologist

Oct. 20 & 27, 2021

Oct. 27, 2021:

  • COVID-19 and nails: A review of clinical findings

  • DermWorld Insights and Inquiries: Taking woolly hair to heart

  • Derm Coding Consult: CMS revises Advance Beneficiary Notice of Non-coverage (ABN) requirements

  • Categorization of cutaneous COVID-19 vaccine reactions

  • FDA approves first interchangeable biosimilar to adalimumab

  • Facing a trifecta of Medicare physician payment cuts Jan. 1, 2022, here’s what the AADA is demanding on behalf of the specialty

Oct. 20, 2021:

  • AADA advocacy results in FDA approving iPLEDGE modifications

  • DermWorld Insights and Inquiries: Probing pediatric pigmented purpuras

  • DermWorld Young Physician Focus: Staying connected

  • Scabies treatment may be less effective

  • Hidradenitis suppurativa hospital readmission rate

  • AAD mourns the passing of Gloria Flippin Graham, MD, who helped establish the Women’s Dermatologic Society

  • HHS renews public health emergency

Oct. 6 & 13, 2021

Oct. 13, 2021:

  • How does wearing occlusive gloves impact hand eczema?

  • DermWorld Insights and Inquiries: What’s up in Down syndrome?

  • Relief funds available for health care providers, including some reserved for rural practices. Apply by Oct. 26.

  • New AAD-supported ICD-10 codes for moisture-associated skin damage approved

  • FDA warns against use of needle-free devices for dermal filler injections

  • CMS updates MIPS 2022 payment adjustments, 2020 MIPS performance feedback

  • United adjusts dermpath program, delays until 2022

Oct. 6, 2021:

  • A review of oral nail growth supplements

  • DermWorld Insights and Inquiries: Granular detail on granular parakeratosis

  • Coding guidance on reporting lesion services

  • Implementation of COVID-19 phototherapy guidelines

  • FDA recalls compounding pharmacy products

Sept. 15, 22 & 29, 2021

Sept. 29, 2021:

  • Is HPV vaccination associated with clearance of common warts?

  • DermWorld Insights and Inquiries: Positively perplexing — Determining the meaning of CD30 positivity

  • FDA proposes new guidance on OTC sunscreen products and safety information

  • FDA approves first topical JAK inhibitor for atopic dermatitis

  • COVID-19 infection in a vaccinated health system

Sept. 22, 2021:

  • What treatment is most effective for refractory spontaneous urticaria?

  • DermWorld Insights and Inquiries: Following up on “A Trend I Cannot Endorse”

  • DermWorld Young Physician Focus: Serendipity

  • Lawsuit filed against FDA for alleged inaction on hair loss drug potential side effects

  • Dermatologist Seemal R. Desai, MD, FAAD, reappointed to FDA Pharmacy Compounding Advisory Committee

  • Hurricane Ida triggers MIPS extreme and uncontrollable circumstances policy

Sept. 15, 2021:

  • Worsening psoriasis after COVID-19 vaccination

  • DermWorld Insights and Inquiries: Is ivermectin an old drug with new tricks?

  • Frontal fibrosing alopecia and facial care products

  • Biden administration announces employee vaccination mandates

  • Do hormones, reproduction play a role in incident rosacea?

Sept. 1 & 8, 2021

Sept. 8, 2021:

  • A review of spironolactone for androgenetic alopecia

  • DermWorld Insights and Inquiries: Alarming but benign – The enigma of acute hemorrhagic edema of infancy

  • What are the long-term clearance rates for actinic keratosis interventions?

  • FDA issues safety warning for JAK inhibitors that treat inflammatory conditions

Sept. 1, 2021:

  • Which dermatology patients should receive a third dose of mRNA vaccine?

  • DermWorld Insights and Inquiries: Shedding light on the hydroa vacciniforme-like lymphoproliferative disorder

  • Obesity, diabetes associated with reduced response to biologics

  • No-show rate reduced with teledermatology

  • Information blocking: Make your voice heard

Aug. 18 & 25, 2021

Aug. 25, 2021:

  • TNF inhibitors vs. IL-17/IL-23 inhibitors for psoriasis and PsA

  • DermWorld Insights and Inquiries: Immediate pathology report release to patients — Is the 21st Century CURES Act worse than the disease?

  • Itch in skin of color

  • Quantifying skin conditions from mask-wearing

  • 2020 MIPS performance feedback, final score, and 2022 payment adjustment

Aug. 18, 2021:

  • Evaluating diagnostic accuracy across Fitzpatrick phototypes, skin of color

  • DermWorld Insights and Inquiries: Striving for hard facts about water softening in atopic dermatitis

  • DermWorld Young Physician Focus: Fitting it all in

  • Seeking comments on urticaria guideline

  • COVID-19 breakthrough infections in vaccinated health care workers

Aug. 4 & 11, 2021

Aug. 11, 2021:

  • Topical tofacitinib for alopecia areata affecting facial hair

  • DermWorld Insights and Inquiries: Monitoring infantile hemangiomas — What’s the score?

  • Is there an effective treatment for skin picking disorder?

  • Chilblains before and during the COVID-19 pandemic

  • Efficacy of ruxolitinib cream in vitiligo patients

Aug. 4, 2021:

  • Probiotic supplements improve atopic dermatitis symptoms

  • DermWorld Insights and Inquiries: Keeping abreast of drug-induced cutaneous lupus

  • From mentoring LGBT dermatologists, to caring for HIV patients, GALDA looks back on its 40-year journey

  • FDA approves treatment for adult dermatomyositis

  • Overcoming hurdles in telemedicine

July 21 & 28, 2021

July 28, 2021:

  • OTC hair growth therapies for skin of color patients

  • DermWorld Insights and Inquiries: Putting a finger on the diagnosis of Achenbach syndrome

  • Celiac disease: Which skin conditions may be related?

  • Here’s what it takes to launch a successful Skin Cancer Awareness Month

  • A review of TYK2 inhibitors for dermatologic conditions

July 21, 2021:

  • AADA secures iPLEDGE win

  • DermWorld Insights and Inquiries: Getting to the heart of neonatal lupus erythematosus

  • DermWorld Young Physician Focus: Advancing the cause

  • Cutaneous reactions after mRNA COVID-19 vaccines

  • AMA House of Delegates adopts two resolutions: Non-physician titles, information-blocking rules

July 7 & 14, 2021

July 14, 2021:

  • Acne scarring treatments: What’s most effective?

  • DermWorld Insights and Inquiries: Assessing the significance of a Long-Developed Habit — The role of LDH in dermatology

  • Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice – Part 6

  • Share your comments on the AD comorbidity guideline

  • CMS makes sweeping changes to MIPS quality benchmarks

  • JAAD ranks No. 1 among dermatology journals

July 7, 2021:

  • OTC eczema products with high prevalence of potentially allergenic ingredients

  • DermWorld Insights and Inquiries: Progress in pemphigus — Solidifying rituximab’s role

  • Share your comments on the AD comorbidity guideline

  • An open notes experiment before the information blocking rule

  • Sun-damaged skin and subsequent development of cutaneous squamous cell carcinoma

  • Provider Relief Fund reporting deadline extended

June 16, 23 & 30, 2021

June 30, 2021:

  • Treating atopic dermatitis with cognitive behavioral therapy: Does it work?

  • DermWorld Insights and Inquiries: Deep learning in dermatopathology

  • Sublingual tofacitinib for alopecia areata

  • Biologic psoriasis treatments and risk of nonmelanoma skin cancers

  • AAD adopts updated ACCME disclosure standards for educational presenters

  • AADA's Coding Community will close permanently Aug. 2, 2021

June 23, 2021:

  • Subcutaneous vs. oral methotrexate for psoriasis patients

  • DermWorld Insights and Inquiries: Dermatology and dermatopathology awake — now is the time to embrace the AI revolution

  • Young Physician Focus: Looking back and forging ahead

  • OSHA mandates COVID-19 safety plans for health care workplaces

  • Is male frontal fibrosing alopecia linked to sunscreen, hair care products?

  • AAD mourns the passing of Robert J. Friedman, MD, MSc

  • Join efforts to increase COVID-19 vaccination rates

June 16, 2021:

  • Rituximab vs. mycophenolate mofetil for pemphigus vulgaris

  • DermWorld Insights and Inquiries: Like the tumor itself, knowledge about DFSP is expanding wider and deeper

  • Derm Coding Consult: Applying the 2021 E/M coding concepts in everyday practice – Part 5

  • Methotrexate may decrease effectiveness of Pfizer-BioNTech COVID-19 vaccine

  • Academy member chosen as AMA president-elect

  • Provider Relief Fund reporting deadline extended

June 2 & 9, 2021

June 9, 2021:

  • Merkel cell carcinoma survival by anatomic site

  • DermWorld Insights and Inquiries: Insult to injury — COVID-19-associated mucormycosis

  • Microneedling with topical therapies for melasma

  • Photosensitivity reaction from benzodiazepines

  • Does wildfire air pollution increase atopic dermatitis, itch appointments?

  • AADA opposes physician assistant name change

June 2, 2021:

  • Acne and enthesitis: Is there an association?

  • DermWorld Insights and Inquiries: Touching on contact pemphigus and pemphigus-like eruptions due to imiquimod

  • Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice – Part 4

  • Cutaneous adverse events of immune checkpoint inhibitors

  • Pharmaceutical testing detects high levels of benzene in some sunscreen products

  • Timolol as a high-value treatment for wounds

  • DataDerm™: 2020 MIPS reporting brief

May 19 & 26, 2021

May 26, 2021:

  • Managing itch: Wearable sensor quantifies symptoms

  • DermWorld Insights and Inquiries: Stevens-Johnson Syndrome-toxic epidermal necrolysis — The aftermath

  • Bringing diversity to Academy committees and task forces

  • Is abrocitinib effective for moderate-to-severe atopic dermatitis patients?

  • AMA survey shows more than 50% of physicians work outside private practice

  • CMS reweights MIPS cost category

May 19, 2021:

  • Differentiating early squamous cell carcinoma from actinic keratosis

  • DermWorld Insights and Inquiries: Epidemic of melanoma or epidemic of scrutiny?

  • AAD Board selects Keyvan Nouri, MD, MBA, as next assistant secretary-treasurer

  • DermWorld Young Physician Focus: Coming through the other side

  • Older Americans turn to online ratings to choose physicians

  • Apply for a research grant to support understudied hair disorders

  • FDA publishes notice about environmental impact of certain sunscreen ingredient

May 5 & 12, 2021

May 12, 2021:

  • Telogen effluvium diagnosis during the COVID-19 pandemic

  • DermWorld Insights and Inquiries: For patients with erythropoietic protoporphyria the tide has come in

  • Derm Coding Consult: How does your use of benign and malignant excision codes compare to the derm average?

  • Clear vs. standard masks during outpatient surgical encounters

  • Nationwide global period audit underway

  • Comparative effectiveness trials for topical medications

May 5, 2021:

  • Is dutasteride an effective treatment for frontal fibrosing alopecia?

  • DermWorld Insights and Inquiries: Digging deeper into lupus erythematosus panniculitis

  • Which herbal supplements may affect autoimmune skin diseases?

  • Risk of allergic reaction to COVID-19 vaccine low among patients with allergic skin diseases

  • Grant opportunity: Help increase minority representation in lupus-related clinical trials

  • Academy Advisory Board invites members to submit policy resolutions

April 21 & 28, 2021

April 28, 2021:

  • Acne: Clindamycin-tretinoin vs. benzoyl peroxide-adapalene

  • DermWorld Insights and Inquiries: Do not get burned by missing Staphylococcal scalded skin syndrome

  • Is daylight photodynamic therapy effective for actinic keratosis?

  • Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice – Part 3

  • OIG plans report on dermatologist use of modifier 25

  • Comorbidity screening for hidradenitis suppurativa patients

  • What does the PHE extension mean for telehealth codes?

April 21, 2021:

  • Do hydrolyzed collagen supplements affect skin aging?

  • DermWorld Insights and Inquiries: Nailing down the treatment for ungual melanoma in situ

  • Young Physician Focus: A little help from my friends

  • Isotretinoin management: Store-and-forward vs. live-interactive telemedicine

  • Derm Coding Consult: Audits for skin biopsies, repairs on the rise

  • Share examples of patient harm caused by early release of electronic health information

April 7 & 14, 2021

April 14, 2021:

  • Pulsed dye laser versus ablative fractional CO2 laser for hypertrophic scars

  • DermWorld Insights and Inquiries: LIDA rose the insulin requirement

  • Actinic keratosis clinical guideline published

  • Do mucocutaneous eruptions correlate with COVID-19 severity?

  • What do consumers recall from sunscreen labels?

April 7, 2021:

  • Applying 2021 E/M coding concepts in everyday practice – Part 2

  • DermWorld Insights and Inquiries: Keeping an eye on melanoma

  • AAD collaborates with OM1 to enhance DataDerm™

  • Phase III results revealed for molluscum contagiosum treatment

  • AADA advocates for improved safety oversight for dermal fillers

  • Your patients can help the Academy raise awareness about skin cancer

  • Payment Protection Program extended

March 17, 24, & 31, 2021

March 31, 2021:

  • Studies show skin rashes are highly predictive of positive COVID-19 results

  • DermWorld Insights and Inquiries: Netherton syndrome — From apex to nether

  • New AAD research grant focuses on understudied hair disorders

  • How does COVID-19 impact patients with bullous pemphigoid, pemphigus?

  • FDA accepts AADA’s recommendation to improve access to quinacrine

  • The AAD Virtual Career Fair is virtually here!

March 24, 2021:

  • Derm Coding Consult: Applying 2021 E/M coding concepts in everyday practice — Part 1

  • DermWorld Insights and Inquiries: Lipschütz ulcers — Not only for women

  • Imiquimod vs. photodynamic therapy for actinic keratosis of the scalp

  • No more waiting on EHRs for MIPS!

  • Is mycophenolate mofetil effective for the treatment of cutaneous lichen planus?

  • Does maternal autoimmune disease have an impact on offspring?

March 17, 2021:

  • COVID-19 in melanoma patients

  • DermWorld Insights and Inquiries: Hoops and happiness — Having the courage to take a shot

  • DermWorld Young Physician Focus: Forging ahead

  • Chemical peels for melasma in patients with skin of color

  • Monitoring patients on methotrexate for lab abnormalities

  • Vitiligo patients share struggles, therapeutic needs with FDA

March 3 & 10, 2021

March 10, 2021:

  • Periungual warts: Is intralesional antigen immunotherapy effective?

  • DermWorld Insights and Inquiries: A shot in the dark

  • How does baricitinib fare in alopecia areata?

  • Do calcineurin inhibitors, phototherapy have a risk of skin cancer, lymphoma?

  • UHC extends application deadline for Designated Diagnostic Provider Program

March 3, 2021:

  • The latest on the association between diet and acne

  • DermWorld Insights and Inquiries: Time to reassess messing around with steroids and psoriasis

  • Is intralesional 5-FU effective for nonmelanoma skin cancer?

  • Topical CBD for skin conditions: The known and unknown

  • 2021 AAD election: View ballot book, prepare to cast vote

  • CMS announces automatic exemption for MIPS 2020 performance period, extended deadline for COVID relief

  • When is repayment due for CMS' advance payment program?

Feb. 17 & 24, 2021

Feb. 24, 2021:

  • COVID-19 vaccination for patients on immunotherapies: An evidence-based guide

  • DermWorld Insights and Inquiries: Multiple pilomatricomas by the numbers

  • DermWorld Young Physician Focus: Do you take the ‘wait and see’ approach in your practice?

  • FDA approves HA dermal filler for chin retrusion

  • United to roll out new Designated Diagnostic Provider program; deadline to apply Feb. 28

  • Short-term PPP window open for smaller businesses

  • Meet the candidates for the 2021 AAD election

Feb. 17, 2021:

  • FDA approves cemiplimab for advanced BCC

  • DermWorld Insights and Inquiries: Honing in on diffuse dermal angiomatosis

  • New JAK inhibitor shows notable PASI score improvement

  • Physician perceptions of people with disabilities

  • Minocycline foam label updated with new data

  • CDC issues quarantine recommendations for vaccinated health care workers

Feb. 3 & 10, 2021

Feb. 10, 2021:

  • FDA clears device to improve cellulite

  • DermWorld Insights and Inquiries: Leishmania episode 1a — attack of the clones

  • Distance traveled: Dr. Lim’s diversity focus as Academy president still relevant today

  • Treating vitiligo with apremilast and narrowband UVB in skin of color

  • Isotretinoin vs oral antibiotics: Risk of depression

Feb. 3, 2021:

  • How effective are oral hair growth supplements?

  • DermWorld Insights and Inquiries: Going green — The complexities of the green nail syndrome

  • A practical guide for managing hidradenitis suppurativa patients

  • ABD selects new executive director

  • How effective are educational brochures at encouraging skin cancer screenings?

  • Academy Advisory Board invites members to submit policy resolutions

Jan. 20 & 27, 2021

Jan. 27, 2021:

  • Can dermatology employers require employees to receive the COVID-19 vaccine?

  • DermWorld Insights and Inquiries: Playing the field — Introducing tirbanibulin for actinic keratosis therapy

  • DermWorld Young Physician Focus: Settling into the New Year

  • FDA grants orphan drug designation for advanced melanoma treatment

  • Vitiligo and dementia: Is there a connection?

Jan. 20, 2021:

  • Natural supplements in dermatology: What drugs do they interact with?

  • DermWorld Insights and Inquiries: Olmsted syndrome patients can finally put their foot down

  • Derm Coding Consult: UnitedHealthcare delays Laboratory Test Registry until 2022

  • Vaccinating patients on TNF inhibitors

  • FDA’s Bad Ad Program offers CME opportunity

  • Academy Advisory Board invites members to submit policy resolutions

Jan. 6 & 13, 2021

Jan. 13, 2021:

  • CMS implements congressionally mandated adjustments, avoiding steep Medicare cuts

  • DermWorld Insights and Inquiries: Not aging like fine wine — The myths and mysteries of acquired port wine stains

  • PPP loan forgiveness 101

  • How should dermatologists decide which patients get in-person appointments during a pandemic?

  • Have stretch marks finally met a worthy foe?

  • COVID-19 public health emergency extended

Jan. 6, 2021:

  • Managing pain in hidradenitis suppurativa patients: A proposed algorithm

  • DermWorld Insights and Inquiries: Itching to see if polymerase chain reaction mite be the future of diagnosing scabies

  • 2021 E/M guidance sunscreen update

  • Does exercise affect papulopustular acne?

  • COVID-19 Dermatology Registry accepting vaccine side effect submissions

  • Academy seeks statements on proposed bylaws amendments


2020 issues

Dec. 16 & 23, 2020

Dec. 23, 2020:

  • The impact of COVID-19 on the practice of dermatology

  • DermWorld Insights and Inquiries: Holiday greeting 2020

  • HHS announces additional Medicare relief funding

  • FDA approves topical AK treatment

  • Young Physician Focus: Bidding 2020 farewell (and good riddance!)

  • Three cases of facial swelling reported in Moderna vaccine trial

  • AAD members among Medscape’s 25 Rising Stars

  • iPledge callers experience long wait times

Dec. 16, 2020:

  • What are risk factors for frontal fibrosing alopecia?

  • DermWorld Insights and Inquiries: We’re in hot water! Vibrio vulnificus infections are heading north.

  • Anti-kickback statute implications for company-speaker programs

  • Information blocking rule: What does it mean?

  • Academy seeks statements on proposed bylaws amendments

  • FDA shares voluntary topical drug product recall

Dec. 2 & 9, 2020

Dec. 9, 2020:

  • What are the effects of OTC moisturizers on skin barrier function?

  • DermWorld Insights and Inquiries: Much ado about nothing in dermatopathology

  • CMS fails to prevent Medicare cuts, E/M payment changes move forward

  • ABMS Draft Standards for Continuing Certification Call for Comments delayed until April 2021

  • Participate in the COVID-19 Dermatology Registry

  • Academy seeks assistant secretary-treasurer nominees

  • Deadline extended for MIPS extreme and uncontrollable circumstances application

Dec. 2, 2020:

  • Surgical vs non-surgical interventions for basal cell carcinoma

  • DermWorld Insights and Inquiries: Pigmented onychomatricoma — Avoid getting nailed by misdiagnosis

  • Derm Coding Consult: Coding for preventive skin examination in 2021 and beyond

  • MIPS dates and deadlines: What you need to know

  • How thoroughly are biosimilar products tested?

  • Hurricane Laura, wildfires qualify as national disasters, receive neutral payment adjustment

Nov. 18, 2020

Nov. 18, 2020:

  • Hydrogen peroxide and the common wart: Phase 2 results are in

  • DermWorld Insights and Inquiries: Granulomatous slack skin — More than one type of mimicry

  • FDA loosens restrictions on compounding in physician offices

  • DermWorld Young Physician Focus: You are what you consume

  • Deadline for MIPS extreme and uncontrollable circumstances application approaching

  • FDA releases microneedling device guidance

Nov. 4 & 11, 2020

Nov. 11, 2020:

  • How effective are steroid-sparing agents in treating chronic alopecia areata?

  • DermWorld Insights and Inquiries: Raising a toast to advances in treating alcohol-induced flushing

  • Derm Coding Consult: Coding for office visit evaluation and management (E/M) in 2021 and beyond: FAQs

  • FBI warns of cybercrime threat to health care providers, hospitals

  • Can dermoscopy be used to evaluate skin barrier repair?

  • Academy seeks assistant secretary-treasurer nominees

Nov. 4, 2020:

  • FDA approves OTC head lice lotion

  • DermWorld Insights and Inquiries: Striving to alleviate the physical and emotional scars of central centrifugal cicatricial alopecia

  • The future of telehealth

  • New EHR interoperability rule delayed

  • Derm Coding Consult: Payers to reinstate cost-sharing requirements for virtual appointments

  • Rejected VA claims can now be appealed

  • FDA, UMD seek feedback on compounded drug use

Oct. 21 & 28, 2020

Oct. 28, 2020:

  • Drug may offer prolonged improvement in chronic spontaneous urticaria

  • DermWorld Insights and Inquiries: Looking into the whites of the mouth

  • Why will dermatology experience a 2% payment reduction in 2021?

  • Young Physician Focus: Help wanted

  • Derm Coding Consult: Updated NCCI edits now available

Oct. 21, 2020:

  • Can medical scribes boost physician profits?

  • DermWorld Insights and Inquiries: Can topical ketoconazole tip the scales for acne vulgaris?

  • Providing equitable dermatologic care for people with disabilities

  • Got a story to tell? Share it in DermWorld!

  • E/M coding for 2021: Major changes ahead

  • FDA, UMD seek feedback on compounded drug use

Oct. 7 & 14, 2020

Oct. 14, 2020:

  • OTC scar treatments: What does the evidence say about efficacy?

  • DermWorld Insights and Inquiries: Studying skin aging never gets old — The potential role of oxytocin

  • Medicare advance payment program receives repayment extension

  • Virtual group election period open for MIPS 2021

  • Reducing pain, anxiety for dermatologic procedures using local anesthesia

  • FDA, UMD seek feedback on compounded drug use

Oct. 7, 2020:

  • The costs of prior authorizations in a dermatology department

  • DermWorld Insights and Inquiries: Targeted anti-complement therapy may prove to be a complementary treatment for bullous pemphigoid

  • Derm Coding Consult: CMS modifies the 60-day limit for locum tenens during COVID-19

  • California Governor signs nurse practitioner independent practice law

  • Can COVID-19 be transmitted via wounded skin?

  • HHS announces new provider relief payments

  • Academy seeks assistant secretary-treasurer nominees

Sept. 23 & 30, 2020

Sept. 30, 2020:

  • Private equity in dermatology, health care grows

  • DermWorld Insights and Inquiries: New data to recall when considering radiation recall dermatitis

  • Young Physician Focus: Prepping for round two

  • Practicing cosmetic dermatology during COVID-19

  • FDA, UMD seek feedback on compounded drug use

  • FDA rule allows drug importation from Canada to lower drug prices

Sept. 23, 2020:

  • Nail manifestation and COVID-19: The red half-moon sign

  • DermWorld Insights and Inquiries: The profound dermatologic manifestations of COVID-19: Part VII — Who was that masked man?

  • Derm Coding Consult: E/M utilization in dermatology

  • Dermatology resident develops face masks from recycled medical supplies

  • Therapeutic potential of cannabinoid-based therapy in dermatology

Sept. 2, 9 & 16, 2020

Sept. 16, 2020:

  • Patients who won’t wear a mask: Avoiding a lawsuit

  • DermWorld Insights and Inquiries: Slammed by slime

  • Derm Coding Consult: New CPT code 99072 for COVID-19 PPE

  • Pharmacists can vaccinate kids under latest guidance

  • Got a story to tell? Share it in DermWorld!

  • FDA, UMD seek feedback on compounded drug use

Sept. 9, 2020:

  • What are the cutaneous side effects associated with drugs prescribed for COVID-19?

  • DermWorld Insights and Inquiries: Mentorship mentation — Bringing out the best of us!

  • Derm Coding Consult: CMS resumes medical claim review audits

  • NYT publishes Academy’s response to skin of color article

  • Participate in MIPS cost measure field testing

  • Academy seeks assistant secretary-treasurer nominees

Sept. 2, 2020:

  • What role can dermatologists play in developing a COVID-19 vaccine?

  • DW Insights and Inquiries: Dermatopathology’s taste of honey

  • Non-discrimination protections change under ACA

  • Skin of color dermatology content on Instagram

  • Submit nominations for 2021 Academy election

Aug. 19 & 26, 2020

Aug. 26, 2020:

  • Navigating immunosuppression during a pandemic: A guide for the dermatologist

  • DW Insights and Inquiries: Topical tacrolimus topics

  • Derm Coding Consult: Proposed Medicare fee schedule includes telehealth, E/M coding updates

  • Young Physician Focus: Don’t waste a good crisis

  • Participate in MIPS cost measure field testing

Aug. 19, 2020:

  • Does topical tacrolimus for AD increase cancer incidence in children? Study says ‘no.’

  • DW Insights and Inquiries: Juvenile lichen sclerosus — A loss of innocence

  • Derm Coding Consult: Watch out for MIPS 2019 overpayment and recoupment notification

  • Derm Coding Consult: Streamlining the claim denial process in your practice

  • AAD and NPF release psoriasis guidelines on topical treatments

  • Participate in MIPS cost measure field testing

Aug. 5 & 12, 2020

Aug. 12, 2020:

  • Treating trichotillomania: Beyond antidepressants

  • DW Insights and Inquiries: Mogamulizumab for CTCL — Targeted therapy and immunotherapy crossing paths

  • 2021 Medicare fee schedule rewards cognitive work, but cuts procedures

  • Executive Order on improving rural health, telehealth access

  • Dermal absorption of topical drugs

  • Academy seeks assistant secretary-treasurer nominees

Aug. 5, 2020:

  • COVID-19 and employed physicians: Contracts, furloughs, and termination

  • DW Insights and Inquiries: Unmasking the complications of personal protective equipment

  • AAD-NPF release psoriasis guidelines on topical treatments

  • Participate in MIPS cost measure field testing

  • Keeping the frontline workers safe

  • HHS extends CARES Act Provider Relief Fund application deadline to Aug. 28

  • Submit nominations for the 2021 Academy election

July 22 & 29, 2020

July 29, 2020:

  • COVID-19: The impact on employed dermatologists

  • DW Insights and Inquiries: The profound dermatological manifestations of COVID-19 part VI — Going to the dogs

  • Young Physician Focus: When it rains, it pours

  • Dermatologic concerns for transgender patients

  • Dermatology drive-thru during COVID-19

July 22, 2020:

  • AK draft guidelines released: Submit your comments

  • DW Insights and Inquiries: Why you should hear about the red ear syndrome

  • Proposed 2021 Medicare changes: What should dermatologists expect?

  • Topical resorcinol as long-term treatment of mild to moderate hidradenitis suppurativa

  • Got a story to tell?

  • On the front lines in Boston

  • Academy seeks assistant secretary-treasurer nominees

  • Register for HHS Telemedicine Hack

July 1, 8 & 15, 2020

July 15, 2020:

  • JAAD study demonstrates direct link between chilblains and COVID-19

  • DW Insights and Inquiries: Incysting on understanding pilar cysts

  • Derm Coding Consult: Practical applications of 2021 E/M coding changes

  • AAD seeks member comments for AK guidelines

  • Caring for their own

  • Submit nominations for 2021 Academy election

July 8, 2020:

  • Chilblains and COVID-19: Is there an association?

  • DW Insights and Inquiries: Et tu, ibrutinib?

  • How to treat nail lichen planus during the COVID-19 pandemic

  • CMS publishes 2019 Open Payments data

  • Being there

  • FDA, M-CERSI to host virtual workshop on topical drug development

  • Paycheck Protection Program deadline extended to Aug. 8

July 1, 2020:

  • Derm Coding Consult: E/M coding — What has changed?

  • DW Insights and Inquiries: Spironolactone — An increasingly recognized hero in acne therapy

  • Is it ethical to charge patients an infection control fee?

  • On the front lines in Connecticut

  • CMS announces relief for 2020 MIPS participants

  • Academy seeks assistant secretary-treasurer nominees

June 17 & 24, 2020

June 24, 2020:

  • Derm Coding Consult: Are you ready for E/M coding changes?

  • DW Insights and Inquiries: Phacing the future — When patients with PHACE syndrome grow up

  • You’re not alone: AAD survey reveals significant impact of COVID-19 on dermatology practices

  • Pride 2020: What is the meaning of Pride and how exactly should it impact our practice?

  • Young Physician Focus: The power of collaboration

  • ECHO on the front lines of COVID-19

June 17, 2020:

  • Treating patients during the COVID-19 pandemic? Here’s how to minimize your malpractice liability risk.

  • DW Insights and Inquiries: Researching therapeutic reformation of the capillary malformation — Arteriovenous malformation syndrome

  • AADA successfully advocates against unfair Medicare prior authorization policy

  • Derm Coding Consult: New interactive evaluation and management resource tool available

  • How does race impact time to treatment for melanoma?

  • Reflections from a dermatologist on a COVID-19 medical ward

  • CMS issues final rule on advancing interoperability, patient access to health data

  • Academy Advisory Board invites members to submit policy resolutions

June 3 & 10, 2020

June 10, 2020:

  • Where is teledermatology most useful? Patient web searches may provide clues.

  • DW Insights and Inquiries: Lichenoid and granulomatous dermatitis — Points to ponder

  • During the COVID-19 pandemic, ‘Leaders eat last.’

  • Two more days…there’s still time to register for AAD VMX

  • Submit nominations for 2021 Academy election

June 3, 2020:

  • COVID-19 and androgenetic alopecia: Is there a link?

  • DW Insights and Inquiries: Clear cell papulosis — Clearly distinctive, clearly underrecognized

  • Register for the Academy’s virtual meeting experience, AAD VMX

  • COVID-19 dermatology registry qualifies as an Improvement Activity

  • Academy seeks assistant secretary-treasurer

  • COVID-19 skin care and hygiene kits for the homeless

  • Academy Advisory Board invites members to submit policy resolutions

May 20 & 27, 2020

May 27, 2020:

  • How to classify COVID-19 rashes

  • DW Insights and Inquiries: On the cusp of extraordinary advances in extramammary Paget disease

  • Derm Coding Consult: Telephone code Medicare reimbursement will be updated automatically

  • Register for the Academy’s virtual meeting experience, AAD VMX

  • Young Physician Focus – Teledermatology: Love it or list it?

  • Stay tuned: New E/M codes

  • From distilleries to the State House: Garnering support during COVID-19

May 20, 2020:

  • COVID-19 and physician compensation: Survey shows likely decline

  • DW Insights and Inquiries: Reopening the dermatologic surgery office in the COVID-19 era

  • Register for the Academy’s virtual meeting experience, AAD VMX

  • Race, equity, and the impact of COVID-19 on African Americans

  • Tell Congress how COVID-19 is affecting your practice and patients

May 6 & 13

May 13, 2020:

  • Caring for older patients during COVID-19? What you need to know.

  • DW Insights and Inquiries: The profound dermatological manifestations of COVID-19: Part V – Pediatric multisystem inflammatory syndrome

  • Register for the Academy’s virtual meeting experience, AAD VMX

  • E/M changes on the horizon

  • “It wasn’t a choice. It was a responsibility.”

  • FDA approves new hyaluronic acid lip filler

  • Derm Coding Consult: CMS clarifies telehealth and telephone coding during COVID-19

May 6, 2020:

  • What dermatologic hazards are COVID-19 health care workers facing?

  • DW Insights and Inquiries: Working up pernio — How far should you dip your toe in the water?

  • Novel topical acne treatment appears to be effective

  • Emergency supply drive for front line COVID-19 workers

  • National Academy of Sciences elects Angela M. Christiano, PhD

  • First open-access papers published in JAAD International

April 15, 22, & 29, 2020

April 29, 2020:

  • Derm Coding Consult answers COVID-19 telehealth coding FAQs

  • DW Insights and Inquiries: Here comes summer (and sunscreen conversations)!

  • Congress passes legislation to provide further COVID-19 relief funding

  • HHS agencies delay new EHR interoperability rules

  • Academy encourages participation in new COVID-19 dermatology registry

April 22, 2020:

  • Are you exempt from the COVID-19 FMLA and paid sick leave provisions?

  • DW Insights and Inquiries: The profound dermatological manifestations of COVID-19: Part IV - Cutaneous features

  • Patients warming to telehealth as an option for care

  • More than 9,000 health care workers infected with coronavirus

  • Academy encourages participation in COVID-19 dermatology registry

April 15, 2020:

  • Derm Coding Consult: Telehealth coding, documentation, and reimbursement during COVID-19: What you need to know.

  • DW Insights and Inquiries: The H syndrome – Understanding Y

  • Academy encourages participation in COVID-19 registry

  • On the front lines of COVID-19

  • Hundreds of thousands of health care workers face layoffs, furloughs during pandemic

  • Medical students may frequently misdiagnose dermatologic disorders in skin of color patients

  • Join the Academy’s skin cancer measure testing project:

April 1 & 8, 2020

April 8, 2020:

  • Employers’ legal responsibilities during COVID-19: What you need to know.

  • DW Insights and Inquiries: The profound dermatologic manifestations of COVID-19: Part III

  • ABD relaxes 2020 MOC requirements

  • Academy election results announced

  • Pilot study examines hydroxychloroquine for COVID-19

  • Social distancing = social learning

April 1, 2020:

  • What to do with iPLEDGE patients during COVID-19

  • DW Insights and Inquiries: Knuckling down on knuckle pads

  • Medicare offers physicians advance payments to address COVID-19 cash-flow issues

  • FDA approves crisaborole for AD patients as young as three months

  • Derm Coding Consult: Guidance on using teledermatology during the COVID-19 pandemic

  • Will ultrasound gel improve wart treatment efficacy?

  • Virginia bans indoor tanning for minors under 18

  • Join the Academy’s skin cancer measure testing project

  • Cast your vote in the AAD election by April 4

March 18 & 25, 2020

March 25, 2020:

  • CMS extends 2019 MIPS reporting deadline

  • DW Insights and Inquiries: The profound dermatologic manifestations of COVID-19 – Part 2

  • Young Physician Focus: A legitimate concern

  • COVID-19 pandemic drains hydroxychloroquine supply

  • Join the Academy’s skin cancer measure testing project

  • FDA, M-CERSI to host virtual workshop on dermal absorption of topicals

  • From COVID-19 to private equity, candidates weigh in on timely issues

March 18, 2020:

  • CMS offers physicians flexibility during COVID-19 emergency

  • DW Insights and Inquiries: The profound dermatological manifestations of COVID-19

  • Feedback requested: AAD/NPF draft guidelines for the management and treatment of psoriasis with topical therapy, complementary and alternative medicine modalities for psoriasis severity measures

  • HHS agencies announce new EHR interoperability rules

  • Coming soon: Cast your vote in the AAD election

March 4 & 11, 2020

March 11, 2020:

  • A guide to managing coronavirus in dermatology clinics

  • DW Insights and Inquiries: The 2020 vision for nemolizumab in atopic dermatitis

  • Feedback requested: AAD/NPF draft guidelines for the management and treatment of psoriasis with topical therapy, complementary and alternative medicine modalities for psoriasis severity measures

  • Brand-name prescription drug prices up 159% since 2007

  • JAAD research finds new link between vitiligo and autoimmune diseases

  • Here’s your chance to get to know the 2020 AAD Election candidates

March 4, 2020:

  • Academy and NPF release new psoriasis guidelines on systemic therapies

  • DW Insights and Inquiries: Anterolateral leg alopecia

  • Choose a Dermatologist: Participate in the AAD’s new social media campaign

  • Amid coronavirus outbreak, FDA takes steps to ensure quality of imported products

  • Insurers offering health care services?

  • Coming soon: Cast your vote in the AAD election

  • Election coverage you don’t want to miss

Feb. 19 & 26, 2020

Feb. 26, 2020:

  • Plantar warts: Shave with PDT or cryotherapy?

  • DW Insights and Inquiries: A niche with NICH

  • Legislators seek to expand sunscreen ingredient ban

  • Young Physician Focus: Giving back

  • Novitas starts Mohs surgery audits

  • Pharmaceutical executive pleads guilty to generic price fixing

  • Just Announced: Meet the AAD 2020 candidates

  • Derm World apologizes for logo use in outside advertising

Feb. 19, 2020:

  • Study raises concerns about skin cancer detection apps

  • DW Insights and Inquiries: Men in the twilight Zoon

  • STD medical claims in the U.S. soar

  • Does tobacco exposure increase risk of pediatric psoriasis?

  • More than 20% of surgery patients have received surprise medical bills

  • Get ready for the 2020 Academy elections

Feb. 5 & 12, 2020

Feb. 12, 2020:

  • FDA prioritizes drug shortages with new approval policy

  • DW Insights and Inquiries: Twenty years of imiquimod taking its toll on lentigo maligna: Where are we?

  • CMS updates MIPS Explore Measures Tool for 2020

  • Derm Coding Consult: AMA CPT releases new online digital E/M services codes for private payers

  • What are the hazardous effects of e-cigarettes on the skin?

  • President Trump declares public health emergency over coronavirus

  • Is nadolol a safe option for infantile hemangioma?

Feb. 5, 2020:

  • Legislators aim to prevent sunscreen bans

  • DW Insights and Inquiries: Prurigo pigmentosa as the “keto rash”: I’m a believer

  • Correction issued to pediatric psoriasis treatment guidelines

  • FDA grants priority review of dupilumab for children

  • Pemphigus vulgaris therapy granted FDA orphan drug status

  • Presentation of evidence on the HPV vaccination

Jan. 22 & 29, 2020

Jan. 29, 2020:

  • Patients are using YouTube to get information on isotretinoin. Here’s what you need to know.

  • DW Insights and Inquiries: Getting steamed over vaping

  • Derm Coding Consult: A New Year’s reminder on preventive services

  • Are your patients at risk? Potent topical corticosteroids sold OTC

  • The whole dermatologist: Beyond the skin

  • How do physicians run for office? The AMA’s workshop will guide you.

  • 2020 QPP resources available in the Resource Library

Jan. 22, 2020:

  • Academy comments on FDA sunscreen study

  • DW Insights and Inquiries: Paradoxical biological reactions and Grandma Dora’s waterbed

  • 2020 kicks off with revised ICR coding guidelines

  • Participate in MGMA's 2020 Compensation and Production Survey

  • Video education, simulation improves surgical training among dermatology residents

Jan. 8 & 15, 2020

Jan. 15, 2020:

  • Which cosmeceuticals have proven clinical efficacy?

  • DW Insights and Inquiries: Thoughts on hyaluronidase and The House of God

  • Cancer death rate falls by largest one-year drop on record

  • How do physicians run for office? The AMA’s workshop will guide you.

  • Check your 2020 MIPS eligibility

Jan. 8, 2020:

  • FDA’s biotin warning: Was it enough to educate physicians, patients about the risks?

  • DW Insights and Inquiries: Dupilumab’s growing pains

  • 2020 kicks off with revised ICR coding guidelines

  • Join the Academy’s skin cancer measure testing project

  • FDA warns about respiratory problems with gabapentin

  • 2019 MIPS data submission period is open


2019 issues

Dec. 4, 11 & 18, 2019

Dec. 18, 2019:

  • Which physicians were sued most in 2019?

  • DW Insights and Inquiries: Holiday greeting 2020 — eyeing dermatology’s future

  • New DW Academy Insider coming in 2020

  • Does teledermatology improve PCP-delivered care for disadvantaged patients?

  • Learning to fail

  • Senate confirms Hahn to lead the FDA

  • Virtual group election period open for MIPS 2020 performance period

Dec. 11, 2019:

  • Physician depression increases medical errors…increasing depression

  • DW Insights and Inquiries: Topical retinoid therapy for acanthosis nigricans — in the thick of it

  • MIPS: What you need to know now — and what’s ahead

  • Leveraging virtual networks to improve dermatologic access and care

  • Why are females less satisfied with biologic treatments for psoriasis?

  • New Medicare card transition period ending

Dec. 4, 2019:

  • New opioid prescribing guidelines for dermatologic procedures

  • DW Insights and Inquiries: Beware — discordance abounds among pathologists in the diagnosis of melanocytic neoplasms

  • Prepare for next month’s intermediate and complex repair coding guidelines updates

  • 2019 AMA House of Delegates Meeting: Regulation of PAs, board certification standards, and more


Nov. 6, 13 & 20, 2019

Nov. 20, 2019:

  • Which types of dermal fillers are associated with increased complications?

  • DW Insights and Inquiries: Rituximab and dermatomyositis — Dr. Samitz would be proud

  • An ode to the good old days

  • CMS issues final and proposed rules to increase price transparency

  • Dermatologists bridge gaps in rural care access

  • Join the Academy’s skin cancer measure testing project

  • Virtual group election period open for MIPS 2020 performance period


Nov. 13, 2019:

  • New recommendations for detecting noninvasive melanoma published

  • DW Insights and Inquiries: The naked truth about total body skin examination — A lesson from Goldilocks and the Three Bears

  • Apply or nominate a colleague for Advocate of the Year

  • Health Affairs highlights dermatologist voices in new series

  • New Medicare card transition period ending

  • MIPS extreme and uncontrollable circumstances policy expands to new areas

Nov. 6, 2019:

  • SPF 50+ vs. 100+ — is there a difference?

  • DW Insights and Inquiries: Getting the gist of GIST cutaneous hyperpigmentation disease

  • Academy announces new Executive Director and CEO

  • Academy releases joint guidelines for psoriasis in pediatric patients

  • AAD/A members vote to remove Board member

  • Join the Academy’s Skin Cancer Measure Testing Project

  • Federal report addresses drug shortage causes, potential solutions

Oct. 23 & 30, 2019

October 30, 2019:

  • Potential treatment for chronic urticaria may offer complete control

  • DW Insights and Inquiries: Can chowing down improve pseudoxanthoma elasticum?

  • Advances in medical technology: friend or foe?

  • Do U.S. dermatology residents suffer from imposter syndrome?

  • Syphilis and STDs on the rise for fifth year in a row

October 23, 2019:

  • Treating molluscum contagiosum: Ingenol mebutate vs. imiquimod

  • DW Insights and Inquiries: Coming clean on bleach baths for atopic dermatitis

  • Ancestry launches consumer genetic health testing

  • CMS offers new MIPS resources

  • Florida bill proposes requiring prescriptions for sunscreens that could harm coral reefs

  • World Psoriasis Day is approaching

Oct. 2, 9 & 16, 2019

October 16, 2019:

  • Is there a link between lupus and prescription opioids?

  • DW Insights and Inquiries: Nonepidemic Kaposi sarcoma: The fifth dimension

  • Academy cautions members of fraudulent email solicitations promoting sale of AAD’s Annual Meeting attendee list

  • Updated AAD.org puts most-used content at members’ fingertips

  • GAO interviews Academy experts on sunscreen safety testing

  • New Medicare card transition period ending

  • AAD diversity workshop addresses disparities in dermatology

October 9, 2019:

  • Topical calcineurin inhibitors vs. topical corticosteroids for vitiligo

  • DW Insights and Inquiries: Glucose monitors — Not as sweet as they seem

  • American Board of Dermatology announces alternative to MOC exam

  • Upcoming coding changes: Differentiating intermediate from complex repairs

  • Academy supports legislation that would ensure patient access to medication

  • Virtual group election period open for MIPS 2020 performance period

  • President Trump executive order calls for sweeping changes to Medicare Advantage

October 2, 2019:

  • Does gluten increase risk for psoriasis and AD in women?

  • DW Insights and Inquiries: Cutting giant congenital nevi down to size molecularly

  • Upcoming coding changes: Differentiating intermediate from complex repairs

  • Apple cider vinegar soaks to treat AD: Yea or nay?

  • Which dermatologic conditions have the highest hospital readmission rates...and what's the cost

Sept. 18 & Sept. 25, 2019

September 25, 2019:

  • Which biologics cause weight gain in psoriasis patients?

  • DW Insights and Inquiries: I never wanted chaperones — until now

  • Two sides to every story

  • Academy's contribution to skin cancer prevention shows nationwide progress  

  • Physician burnout is real, but AADA's DERM360 resources can help 

  • Quinacrine dihydrochloride recalled by Darmerica

  • Nominations sought for 2020 Academy election

September 18, 2019:

  • HPV vaccine to treat common warts?

  • DW Insights and Inquiries: Calcipotriene and 5-fluorouracil — Dermatology’s new dynamic duo?

  • Government green-lights co-pay accumulator programs for 2020

  • Howard Rogers, MD, testifies to House committee about prior authorization burdens

  • Hurricane Barry triggers MIPS extreme and uncontrollable circumstances policy

  • Medicare Beneficiary Identifier (MBI) transition period nearing its end

Sept. 4 & Sept. 11, 2019

September 11, 2019:

  • How often do dermatologists prescribe off-label medications?

  • DW Insights and Inquiries: Shingles and the battle of the bulge

  • Feedback requested: AAD/NPF draft guidelines for the management of psoriasis with non-biologics

  • Deadline approaching to submit a 2018 MIPS targeted review request

  • FDA expands approval of two topical psoriasis therapies to pediatric patients

  • Grants available for technology-based teaching applications

September 4, 2019

  • New Drug Application submitted for rosacea topical treatment

  • DW Insights and Inquiries: Parabens — A common allergen with lots of hype and no real harm

  • Feedback requested: AAD/NPF draft guidelines for the management of psoriasis with non-biologics

  • AAD media coverage on sun protection earns one billion media impressions

  • Nominations sought for 2020 Academy election

Aug. 21 & Aug. 28, 2019

August 28, 2019:

  • Dupilumab shows positive results for younger atopic dermatitis patients

  • DW Insights and Inquiries: Finding joy in pediatric phototherapy

  • FDA, UMD seek feedback on compounded drug use

  • California, New York ban discrimination against natural hair

  • Grants available for technology-based teaching applications

August 21, 2019:

  • FDA grants breakthrough therapy designation to advanced melanoma treatment

  • DW Insights and Inquiries: Rejecting preconceived notions of squamous cell carcinomas in patients experiencing transplant rejections

  • Quality Payment Program hardship exemption applications now available

  • New hidradenitis suppurativa guidelines highlight disease complexity

  • Submit an abstract for the Gross and Microscopic Symposium

Aug. 7 & Aug. 14, 2019

August 14, 2019:

  • CMS seeks to reduce prior authorization burden on physicians

  • DW Insights and Inquiries: Putting muscle into isotretinoin laboratory testing isn’t chopped liver!

  • Applicants sought for research excellence awards for young dermatology investigators

  • Medicare Beneficiary Identifier (MBI) transition period nearing its end

  • Nominations sought for 2020 Academy election

August 7, 2019:

  • What effect has iPLEDGE had on pregnancy rates?

  • DW Insights and Inquiries: Snitching on Schnitzler syndrome — The continuing search for an optimal biomarker

  • U.S. Virgin Islands bans sunscreen with oxybenzone and octinoxate

  • Joint clinical guidelines provide evidence-based practices for treating psoriasis 

  • Submit an abstract for the Gross and Microscopic Symposium

July 24 & July 31, 2019

July 31, 2019:

  •  Academy and NPF release new psoriasis phototherapy guidelines

  • DW Insights and Inquiries: A metabolic pathway that may allow dermatologists to run rings around porokeratoses

  • Having trouble finding diphenylcyclopropenone?

  • Submit an abstract for the Gross and Microscopic Symposium

  • Nominations sought for 2020 Academy election

July 24, 2019:

  • Wound care after dermatologic procedures lacks uniformity

  • DW Insights and Inquiries: Eosinophilic dermatosis of hematologic malignancy: Reality bites

  • A look back at dermatology’s past with an eye on the future

  • A customized vaccine for advanced melanoma?

  • Call for nominations for 2020 AAD election

  • House votes to repeal ‘Cadillac Tax’

  • Sheila F. Friedlander, MD, to present on dermal absorption at Univ. of Maryland School of Pharmacy workshop

July 3, July 10 & July 17, 2019

July 17, 2019:

  • Isotretinoin, depression, and suicide: What’s the connection?

  • DW Insights and Inquiries: Should dermatologists be anti-antihistamine for atopic dermatitis?

  • 2018 MIPS performance feedback, final score, and targeted review now available

  • Natural skin care regimen vs. synthetic regimen for managing rosacea

  • Two more speakers confirmed for 2019 AADA Legislative Conference

July 10, 2019:

  • FDA clears new body sculpting device

  • DW Insights and Inquiries: The pachydermoperiostosis prostaglandin paradigm

  • Increase in demand triggers shortage of intravenous immunoglobulin

  • Patient Access Hero: Dallas clinic provides free multidisciplinary care

  • Miami Beach Commission Sustainability and Resiliency Committee rejects sunscreen ingredient ban

July 3, 2019:

  • Academy comments on FDA sunscreen proposal

  • DW Insights and Inquiries: Oy, another “Oid” to worry about — cryptococcoid lesions

  • VA launches Community Care Network to provide better access to care

  • CMS has begun MIPS data validation, audits for 2017 and 2018 performance years

  • What happened at the AMA House of Delegates meeting? Private equity, compounding, and more.

  • CMS proposes Medicare Part D electronic prior authorization standards

June 19 & June 26, 2019

June 26, 2019:

  • CMS/NCCI changes to PTP edits go into effect next week

  • DW Insights and Inquiries: Conceptualizing atypical fibroxanthomas, pleomorphic dermal sarcomas, and undifferentiated pleomorphic dermal sarcomas

  • Beyond the specialty: How AccessDerm helps primary care providers

  • How do melanoma patients view skin self-examinations?

  • Delaware governor signs critical step therapy bill

June 19, 2019:

  • Do hidradenitis suppurativa patients have a greater comorbidity burden than psoriasis patients?

  • DW Insights and Inquiries: The newest frontier for biologics and psoriasis may be adherence

  • Complimentary webinar: FDA's proposed sunscreen rule — what safety data is the FDA looking for and why?

  • Private equity by the numbers

  • Media personality Michael Smerconish will offer keynote at 2019 AADA Legislative Conference

  • 2020 committee appointment application now open

June 5 & June 12, 2019

June 12, 2019:

  • A new way to treat warts? Heat may be the answer.

  • DW Insights and Inquiries: Taking the challenge: Social media, adolescents, and the skin

  • Dollars and cents: What’s the cost of physician burnout?

  • CMS seeks input for reducing administrative, regulatory burdens

June 5, 2019:

  •  Self-injection of black market dermal fillers poses health concern

  • DW Insights and Inquiries: Stress2 + Hormones2 = Acne2

  • CMS/NCCI announce changes to PTP edits

  • New survey highlights impact of local anesthetics shortage

  • FDA approves first treatment for graft versus host disease

  • What’s the direct liability for business associates under HIPAA?

  • 2020 committee appointment application now open

     

May 22 & May 29, 2019

May 29, 2019:

  • Academy issues statement on sunscreen safety

  • DW Insights and Inquiries: Life is just a bowl of cherry angiomas

  • AccessDerm: Serving the underserved

  • Anthem enforces modifier 25 denials

  • New resolution paves the way for sunscreen in schools and sun-safe education for kids

  • Kaposi sarcoma treatment gets Breakthrough Therapy designation

  • Patient Care Hero: Could a skin rash provide a clue to this woman’s diagnosis

  • Academy Advisory Board invites members to submit policy resolutions

May 22, 2019:

  • What's happening to practice ownership?

  • DW Insights and Inquiries: Breaking the terbinafine laboratory habit for onychomycosis

  • Do you know how to get to 30 points to avoid a MIPS penalty?

  • Augmented intelligence: The synergy of man and machine to improve patient care

  • Maryland passes under-18 indoor tanning ban

  • CMS takes action to lower prescription drug prices, increase transparency

May 1, May 8 & May 15, 2019

May 15, 2019:

  • Why are psoriasis patients turning to complementary and alternative medicine?

  • DW Insights and Inquiries: Coughing up a new warning for ustekinumab

  • AAD adopts position statement on sexual and gender minority health

  • HHS finalizes rule requiring drug prices to be disclosed in TV ads

  • A cheat sheet to dermatology’s ‘hidden curriculum’ 

  • Dr. Resneck testifies to Congress about drug prices and prior authorization

  • Register for the 2019 AADA Legislative Conference 

  • Academy Advisory Board invites members to submit policy resolutions

May 8, 2019:

  • Skin scratching and intestinal changes: What’s the link?

  • DW Insights and Inquiries: Progress for progressive multifocal leukoencephalopathy

  • New maximum penalties for HIPAA violations

  • Adopt-a-Shade: Working together

  • Teledermatology templates decrease face-to-face referrals

May 1, 2019:

  • FDA approves risankizumab for treatment of plaque psoriasis

  • DW Insights and Inquiries: When assessing morbilliform eruptions think about morbilli (measles)!

  • We want your feedback: Draft psoriasis guidelines for pediatric patients

  • CMS to allow insurers to adopt copay accumulators

  • 3 ways to promote skin cancer awareness this month

  • Preliminary MIPS performance data now available

  • Members of Congress take on sunscreen use

  • NIH to honor dermatologist Stephen I. Katz, MD, PhD, on May 3

  • 2020 committee appointment application now open

April 17 & April 24, 2019

April 24, 2019:

  • Dermal filler may effectively treat facial acne scarring

  • DW Insights and Inquiries: Fever, rash, and lymphadenopathy may be wearing more than one DRESS

  • AAD Board of Directors shed light on the strategic plan’s impact on members

  • Feedback requested: Draft psoriasis guidelines for pediatric patients

  • Deadline to review QPP performance data April 27

  • 2020 committee appointment application now open

April 17, 2019:

  • Having trouble accessing compounded quinacrine tablets? Here’s why.

  • DW Insights and Inquiries: A ‘pregnant pause’ is necessary before concluding on the obstetric risk of vitiligo

  • Lessons learned from the customer service world

  • Let’s talk about leading care teams and other elephants in the room

  • Who are the happiest dermatologists? New survey results have answers.

  • NIH to honor dermatologist Stephen I. Katz, MD, PhD, on May 3

  • Academy committee volunteers need to update their disclosures

April 3 & April 10, 2019

April 10, 2019:

  •  ‘Inactive’ ingredients in pills may cause allergic reaction

  • DW Insights and Inquiries: Is there a best approach to widespread actinic keratoses?

  • What’s the optimal way to perform total body skin examinations?

  • Study shows medical spa oversight needs improvement

  • Deadline to review QPP performance data April 27

April 3, 2019

  • Can the elimination diet hurt pediatric atopic dermatitis patients?

  • DW Insights and Inquiries: Tofacitinib – a JAK inhibitor of all trades

  • Unity in dermatology starts with putting patients first 

  • Acne risk in transgender men treated with testosterone

  • Ixekizumab sustains plaque psoriasis improvements, quality of life for one year

  • American Academy of Dermatology announces Interim Executive Director

March 20 & March 27, 2019

March 27, 2019

  • Academy forms task force to address FDA proposed rule on sunscreen monograph, ingredients

  • DW Insights and Inquiries: Biting my nails worrying about atypical presentations of nail unit melanomas

  • Real-time patient data transforms the practice and improves care

  • Joint position statement educates policymakers on safe in-office preparation of buffered lidocaine by dermatologists

  • Patient Care Heroes: Carrie Kovarik, MD, and Keith Hamilton, MD

March 20, 2019:

  • Sodium bicarbonate injection recalled due to presence of glass

  • DW Insights and Inquiries: Dermatologists will increasingly meet mammalian meat allergy

  • Diversifying the specialty can result in high-quality access to dermatologic care

  •  Trouble getting off-label meds? Flawed compendia causing coverage denials for dermatologic conditions

  • Miami Beach commissioners vote ‘no’ on sunscreen ingredient prohibition

March 6 & March 13, 2019

March 13, 2019:

  • Is routine laboratory monitoring for isotretinoin patients necessary?

  • Welcome to Dermatology World Insights and Inquiries

  • Innovative learning experiences equip members to provide compassionate patient care

  • Scientists report curing HIV-positive patient for a second time

  • Hidradenitis suppurativa linked to cardiovascular disease

  •  FDA statement discusses plan for naming biological medicines

March 6, 2019:

  • FDA approves self-injection of guselkumab for plaque psoriasis 

  • Nearly 80% of public find drug prices 'unreasonable'

  • Biotin supplementation unnecessary for most patients, may lead to misdiagnosis

  • Why are academic dermatologists burned out?

Feb. 20 & Feb. 27, 2019

February 27, 2019:

  • FDA approves new neurotoxin for frown lines

  • Breaking down the FDA’s new sunscreen proposal 

  • Update on Anthem instituting new modifier 25 payment policy

  • A new way to help diagnose allergic versus irritant contact dermatitis

  • Dermatologists concerned over use of equine medicine to treat rosacea

  • AAD and NPF release new guideline for treatment of psoriasis with biologics

  • Skin biopsy rate: An assessment of provider utilization

February 20, 2019:

  • Biologics may help fight heart disease in psoriasis patients

  • AAD mourns the passing of Richard L. Dobson, MD

  • Feedback requested: AAD joint guideline for reconstruction after skin cancer resection

  • Severe atopic dermatitis guidelines developed

  • Private payer issues with new biopsy codes

  • Tool may help predict melanoma recurrence after negative SNB

  • View candidates and ballot book online

Feb. 6 & Feb. 13, 2019

February 13, 2019:

  • Do biologics have more adverse events than conventional therapies? Researchers say 'No.'

  • AAD Strategic Plan driven by member feedback

  • Feedback requested: AAD/ASPS joint guideline for reconstruction after skin cancer resection

  • Medicare Administrative Contractors (MACs) deny Mohs with IHC claims

  • Academy leaders convene on Capitol Hill for first Academy Leadership Day

  • How much does having atopic dermatitis cost patients?

  • 2019 AAD Election ballot packet moved online

February 6, 2019

  • Nearly half of U.S. physicians are burned out

  • AAD/A CEO announces departure this spring

  • Anthem to institute new modifier 25 payment policy

  • Researchers create new protein that may help cancer patients

  • HHS proposes to end PBM rebate protections

  • Who has access to dermatology services?

  • NCCI and CMS address modifier 59 issues

  • 2019 AAD Election ballot packet moved online

Jan. 23 & Jan. 30, 2019

January 30, 2019:

  • Dermatologists prescribe fewer antibiotics overall, but use increased with surgery

  • CMS updates Open Payments data

  • What causes allergic responses in patients with atopic dermatitis?

  • YouTube videos about psoriasis biologics

  • Is a new type of treatment for alopecia on the horizon?

  • Palmetto GBA Jurisdiction J and M LCD #33445 affecting dermatology practices in several states

January 23, 2019:

  • How does skin age? Researchers may have found the answer.

  • AAD refutes misleading sunscreen article

  • Taking the pain out of prior authorization denials

  • Academy responds to Vision for the Future Commission draft report

  • NCCI and CMS address modifier 59 issues

  • Virginia Board of Medicine audits compounding practices

  • 2019 AAD Election ballot packet moved online 

Jan. 9 & Jan. 16, 2019

January 16, 2019:

  • Isotretinoin may change bacteria levels on skin of acne patients

  • Using DataDerm™ to seamlessly report for MIPS

  • We want your feedback: Psoriasis draft guidelines

  • Cochrane collection gathers new diagnostic test accuracy reviews for skin cancer

  • New guideline available for infantile hemangioma treatment

  • It’s time to use the new biopsy codes: Do you know how to use them?

  • Remembering Stephen I. Katz, MD, PhD

  • Academy Advisory Board invites members to submit policy resolutions

January 9, 2019:

  • Smartphone app improves treatment adherence for psoriasis patients

  • AAD mourns the passing of Stephen I. Katz, MD, PhD

  • Submit your comments on psoriasis draft guidelines

  • The Academy kicks off 2019 with a new Strategic Plan

  • Increased competition causes falling prices for infliximab and biosimilars

  • 2019 AAD Election ballot packet moved online

  • 2018 MIPS data submission period now open


2018 issues

December 2018

December 19, 2018:

  • A new frown line treatment – coming soon?

  • The AAD 2019 Strategic Plan: Our vision for the future

  • December Heroes: Jean Pierre Galliani, MD, and Naomi Johansen, MD

  • New guidelines issued for treating psoriatic arthritis

  • It’s almost time to use the new biopsy codes: Do you know to use them?   

December 12, 2018:

  • Trouble prescribing isotretinoin to new patients?

  • New tax bill would repeal indoor tanning tax

  • Are you smarter than DataDerm?™

  • Apply for the AAD’s Cochrane Scholarship

  • Academy Advisory Board invites members to submit policy resolutions

  • Keep dermatology’s voice strong: Join the AMA

December 5, 2018:

  • USP update on access to buffered lidocaine

  • Are you smarter than DataDerm™?

  • What’s the latest on drug shortages?

  • Identifying, treating rosacea in skin of color

  • 2019 AAD Election ballot packet moved online

November 2018

November 28, 2018:

  • A biologic for adolescent AD patients: Coming soon?

  • MIPS in 2019: Changes are coming

  • CMS seeks to implement real-time drug pricing widgets

  • Are you smarter than DataDerm™?

  • FDA attempting to get out ahead of drug shortages

  • Help the Academy keep dermatology’s voice strong: Join the AMA

  • CMS conducting new survey on post-op visits in global surgical codes

November 14, 2018:

  • 2019 Fee Schedule – You asked. DWW answers.

  • November Patient Care Hero: Jessica Burgy, MD

  • Are you smarter than DataDerm™?

  • CMS conducting new survey on post-op visits in global surgical codes

  • The MIPS results are in: How did participants perform in 2017?

  • FDA wants to hear from consumers about allergens and cosmetics

  • Dermatologist, pediatrician win congressional seats

November 7, 2018:

  • Fee Schedule: How will your practice fare in 2019?

  • Adopt-a-Shade: Giving kids a safe place to play

  • Academy releases guidelines for melanoma treatment

  • Are you smarter than DataDerm?

  • New psoriasis biologic now available in the United States

  • FDA to ban lead from hair products

Oct. 24 & Oct. 31, 2018

October 31, 2018:

  • Oral antibiotic gets FDA approval for acne

  • Teamwork Hero: Steven Daveluy, MD

  • ABMS approves Micrographic Dermatologic Surgery subspecialty

  • Are you smarter than DataDerm?

  • Trump administration announces plans to lower drug costs

  • Study: Topical tranexamic acid may be effective for erythematotelangiectatic rosacea

  • Older adults opt for fewer medications

October 24, 2018:

  • Drug shortages affecting your patients? Tell the FDA.

  • When dealing with payers, the data can speak for itself

  • Are you smarter than DataDerm™?

  • Adalimumab biosimilar launches in 28 countries

  • President Trump signs legislation prohibiting gag clauses

  • HHS calls for drug prices in television ads

Oct. 3, Oct. 10 & Oct. 17, 2018

October 17, 2018:

  • CMS to conduct new survey on post-op visits in global surgical codes

  • Are you smarter than DataDerm™?

  • ICD-10 updates impact several MIPS quality measures

  • CMS to waive Medicare requirements for providers affected by Hurricane Michael

  • Academy seeks statements on proposed bylaws amendments

  • Help the Academy keep dermatology’s voice strong: Join the AMA

October 10, 2018:

  • CMS to make physicians’ offices fax-free by 2020

  • Are you smarter than DataDerm™?

  • Issue breakdown: Compounding standard would disrupt care

  • AI trained to classify common dermatopathology diagnoses

  • AAD updates “Find a Dermatologist” tool — have you updated your profile?

  • Study suggests minority residents face extra workplace burdens

October 3, 2018:

  • Budget bill includes wins for dermatology

  • AAD updates “Find a Dermatologist” tool — have you updated your profile?

  • Are you smarter than DataDerm™?

  • Did CMS miscalculate your MIPS?

  • Perioral rejuvenation with hyaluronic acid fillers improved projected first impressions

Sept. 19 & Sept. 26, 2018

September 26, 2018

  • Drug prices spike after shortages

  • September Access Hero: Dr. Jonathan Silverberg

  • Dupilumab improves adolescent atopic dermatitis, quality of life

September 19, 2018

  • More than 25% of Americans surveyed think psoriasis is contagious

  • What did the AADA have to say about the proposed fee schedule?

  • Atopic dermatitis associated with depression, anxiety, and suicidal ideation

  • Have you joined the JAAD Journal Club yet?

  • Risk for surgical-site infection increased in lower extremity Mohs surgery

Sept. 5 & Sept. 12, 2018

September 12, 2018

  • CMS continues to tinker with MIPS in 2019 proposal

  • Experimental acne vaccine targets skin bacteria

  • Call for nominations deadline is Oct. 1

  • Hospitals launch generic drug company

  • Rosacea is drastically underdiagnosed, according to study

  • How effective are natural ingredients at UV protection?

  • Voice your opposition about repealing the indoor tanning tax

September 5, 2018

  • CMS values virtual visits

  • AMA House of Delegates votes on critical health policy resolutions 

  • High drug costs send patients seeking foreign medications

  • FDA approves tretinoin lotion for acne

  • Brief dermatologist intervention increases sunscreen use, patient satisfaction

Aug. 22 & Aug. 29, 2018

August 29, 2018

  • CMS questions global payment codes

  • Non-physician clinicians bill more dermatologic procedures

  • Can machine learning exacerbate health care disparities in dermatology?

  • Mediterranean diet may help ease psoriasis severity

  • Compounds in maple leaves may prevent wrinkles

August 22, 2018

  • 6 new biopsy codes for 2019

  • August Access Hero: Jessica Burgy, MD

  • Submit your comments on psoriasis draft guidelines

  • 2018 QPP exception applications now available

  • Ortho Dermatologics resubmits New Drug Application for plaque psoriasis lotion

Aug. 1, Aug. 8 & Aug. 15, 2018

August 15, 2018

  • The good, the bad, and the unknown in CMS E/M proposals 

  • DataDerm™: Better your practice, better the specialty

  • FDA approves new drug to treat cutaneous T-cell lymphoma

  • Dermatologist compensation growth stalls in 2017, survey shows

  • 2017 MIPS performance feedback and payment adjustment

  • Brent Moody, MD, wins Republican primary in Tennessee 

August 8, 2018

  • Fee schedule: The good, the bad, and the ugly 

  • August Access Hero: Cory Simpson, MD

  • USP publishes proposed revisions to chapter on compounded sterile preparations

  • CDC offers infection prevention guide as patient infection incidents increase

  • Severity of atopic dermatitis tied to risk of cataracts among pediatric patients

  • Tickborne diseases are likely to increase, warn NIH officials

August 1, 2018

  • Physicians suing patients over negative reviews

  • FDA to laser device manufacturers: Stop marketing for vaginal rejuvenation

  • FDA releases biosimilars plan to increase access, encourage competition

  • Blood test may be able to detect melanoma

  • Health care cyberattacks on the rise, sensitive data exposed

  • FDA grants orphan drug status to dermatomyositis drug

July 18 & July 25, 2018

July 25, 2018:

  • FDA takes steps to address, prevent drug shortages 

  • Distinction between inflammatory, neuropathic pruritus relevant for care

  • Melanoma underreported among dermatopathologists

  • Drugmakers rescind price hikes after California law takes effect

July 18, 2018:

  • FDA approves first topical hyperhidrosis treatment

  • CMS proposes major E/M changes, modifier 25 payment reduction: What’s next?

  • Survey indicates residents lack confidence in coding, billing skills

  • ‘Gag clauses’ cause some to pay more for drugs

  • Skin Cancer Prevention Report shows progress, room for improvement

  • Could the HPV vaccine treat squamous cell carcinoma?

  • FDA warns against use of sterile drug products 

July 4 & July 11, 2018

July 11, 2018:

  • Amazon upends drug market with purchase of online pharmacy

  • JAAD paper reviews research on chemical sunscreen and the environment

  • Clarification: FDA response to topical psoriasis treatment application

  • CMS posts 2017 Open Payments data

  • Novel targets, treatments needed for metastatic melanoma

  • FDA commissioner gives statement about compounded drugs

  • Trump administration threatens drug manufacturers 

July 4, 2018:

  • iPLEDGE hits a snag with patients

  • Hawaii governor signs legislation banning sunscreen with oxybenzone and octinoxate

  • Medicare announces new MUE limit for aminolevulinic acid HCI, 10%

  • How did you fare with MIPS in 2017? Take a look

  • FDA withdraws draft guidance on biosimilars

  • Is there a connection between HS and Crohn’s?

June 20 & June 27, 2018

June 27, 2018:

  • FDA does not approve topical psoriasis treatment

  • Medicare to limit reimbursement for aminolevulinic acid HCI, 10%

  • Senators urge FDA to examine drug shortages

  • Sen. Schumer works to pull ‘sunscreen pills’ from market

  • NEW: Urticaria guidelines

  • 2019 committee appointment application now open

June 20, 2018:

  • Robots in medicine are coming, but at what cost?

  • June Access Hero: Dr. Colven

  • Does benzoyl peroxide stain all fabrics?

  • CMS launches new Medicare Card search tool

  • Despite the risks, patients are willing to share their data

  • 2019 committee appointment application now open

June 6 & June 13, 2018

June 13, 2018:

  • FDA approves first hyaluronic acid filler for hands

  • Feedback requested: Primary cutaneous melanoma treatment draft guidelines

  • After 60 years, a new treatment for pemphigus vulgaris

  • Jack Resneck Jr., MD, re-elected to AMA Board of Trustees

  • Older patients slowly warming to telemedicine

  • 2019 committee appointment application now open

June 6, 2018:

  • Feedback requested: Primary cutaneous melanoma treatment draft guidelines

  • Integrating the human touch at the AAD Annual Meeting

  • Insurer reverses onerous isotretinoin policy

  • FDA issues REMS draft guidance for manufacturers

  • CMS releases QPP participation results

  • EB treatment receives rare pediatric disease designation from FDA

  • 2019 committee appointment application now open

May 23 & May 30, 2018

May 30, 2018:

  • FDA issues warning on unapproved sunscreen pills

  • May Access Hero: Karen Edison, MD

  • Study: AI detects skin cancer better than dermatologists

  • BCBS Michigan rescinds modifier 25 reimbursement reduction policy

  • Medical school enrollment is up, but can residency slots keep pace?

  • FDA approves new biologic for psoriasis

  • 2019 committee appointment application now open

May 23, 2018:

  • FDA declines to approve potential frown line treatment

  • AAD Annual Meetings: Vital to resident education and the future of dermatology

  • Dermatologist wins Republican nomination in Pennsylvania congressional primary race

  • VA gives physicians the green light to practice telemedicine across state lines

  • FDA eyeballs artificial intelligence in medicine

  • 2019 committee appointment application now open

May 2, May 9 & May 16, 2018

May 16, 2018:

  • Is your group eligible for MIPS? You’d better check.

  • Be a Skin Cancer Hero this May

  • AADA plans to comment on Trump drug-price proposals

  • Can technology help with treatment adherence?

  • 2019 committee appointment application now open

May 9, 2018:

  • FDA grants lidocaine HCL 1% approval to Spectra Medical

  • AAD Board selects Daniel D. Bennett, MD, as next assistant secretary-treasurer

  • Hawaii passes legislation banning sunscreen with oxybenzone and octinoxate

  • Study shows reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel

  • Academy Advisory Board invites members to submit policy resolutions

  • 2019 committee appointment application now open

May 2, 2018:

  • The clock is ticking: Only a few days left to review your Sunshine Act info

  • PBMs cutting copay coupons from patient deductibles — which could mean soaring prices for your biologics patients

  • The latest cosmetic trend: Preventative Botox

  • CMS to change name of MIPS EHR section

  • Want to know how much your patients’ prescriptions will cost? There’s an app for that.

  • 2019 committee appointment application now open

April 18 & April 25, 2018

April 25, 2018:

  • Who’s better at diagnosing skin cancer: PAs or dermatologists?

  • How is MIPS affecting you? CMS wants to know.

  • New physician compensation report: How does dermatology fare?

  • Medicare erroneously paid for telehealth services

  • 2019 committee appointment application now open

April 18, 2018:

  • Getting too many calls from pharmacists? It could get worse.

  • April Access Hero: Dr. Van Voorhees

  • 2019 committee appointment application now open

  • Not sure you’re eligible for MIPS? Better check.

  • Help wanted: AAD Pruritus Measure Testing Project

April 4 & April 11, 2018

April 11, 2018:

  • How did you fare with MIPS? Take a look.

  • Help wanted: AAD Pruritus Measure Testing Project

  • Indoor tanning bed users not getting screened

  • What is the economic impact of inappropriate cellulitis tests?

  • CDC breaks down HIV incidence, prevalence among MSM

  • HHS launches new initiative to boost patient medical record access

April 4, 2018:

  • Deadline approaching: Review your Sunshine Act info

  • New Medicare card transition to begin this month

  • FDA seeks methods to improve biosimilar pathway

  • iPLEDGE REMS program website experiencing issues

  • Wife of Surgeon General undergoing surgery for recurrent metastatic melanoma

  • New: Guidelines for evaluating hirsutism

  • Does weight affect onychomycosis risk?

March 21 & March 28, 2018

March 28, 2018:

  • The burden of prior authorizations: Is it really that bad?

  • Take the ABMS survey on MOC

  • Help wanted: AAD Pruritus Measure Testing Project

  • FDA approves new psoriasis biologic

  • Health care cyberattacks on the rise

  • When do copayments cost more than drugs? Fairly often, study shows.

March 21, 2018:

  • Walgreens sued over generic drug prices

  • March Access Hero: Dr. Chong

  • Help wanted: AAD Pruritus Measure Testing Project

  • Deadline for 2017 MIPS data submission

  • New poll shows patient-physician communication disconnect

  • USPSTF issues recommendations on skin cancer prevention counseling

  • Help AADA, AMA rein in burdensome regulations, harmful payer policies

March 7 & March 14, 2018

March 14, 2018:

  • FDA approves anti-fungal agent for pediatric patients

  • Bruce H. Thiers, MD, elected incoming president-elect

  • Open Payments review starts next month: Are you ready?

  • Melanoma incidence among young, white women declines drastically

  • New Medicare cards: Educate your patients while they wait

  • FDA to inspect Cantrell Drug Co. compounding facility

  • Pulse check: How are EHR systems faring on interoperability?

March 7, 2018:

  • Is MIPS a burden? Tell CMS and get full credit in 2018.

  • Academy election results announced

  • ABD requests Mohs subspecialty certification

  • AAD relocates headquarters

  • Conversion therapy still common for LGBT population

Feb. 21 & Feb. 28, 2018

Feb. 28, 2018:

  • Another win for dermatology: Anthem rescinds proposed modifier 25 policy

  • Vote in the AAD election by March 3

  • FDA grants rituximab priority review for pemphigus vulgaris

  • CMS eases up on value-based payment focus

  • Do EHRs reduce administrative costs?

  • Laser treatment may improve nail psoriasis severity

Feb. 21, 2018:

  • CMS releases MIPS quality performance scores

  • AAD election

  • Study indicates e-consults improve access to dermatology

  • How helpful is federal research funding?

  • Water systems tainted for many Americans

Feb. 7 & Feb. 14, 2018

Feb. 14, 2018:

  • A win for dermatology: Congress repeals IPAB, stops misvalued codes policy

  • Vote in the AAD election by March 3

  • Are machines poised to replace physicians?

  • Countdown to official Medicare card transition

  • Do pediatric psoriasis patients have a greater risk of developing obesity?

Feb. 7, 2018:

  • Generic drug prices: What to expect in 2018

  • February Access Hero: Dr. Brodell

  • CMS expands ‘Extreme and Uncontrollable Circumstances’ policy

  • Network inaccuracies worsen

  • Fewer physicians opting out of Medicare

Jan. 24 & Jan. 31, 2018

Jan. 31, 2018:

  • First IGA scale for EB simplex validated

  • AAD election candidates announced

  • FDA to revise draft guidance affecting in-office preparations

  • How do different SPFs compare?

  • Alex Azar confirmed as HHS Secretary

  • NMQF accepting nominations for Leaders in Minority Health Awards

Jan. 24, 2018:

  • Psoriasis treatments: Which ones are the most effective?

  • AAD names Dirk Elston, MD, next JAAD editor

  • SCC death reports may be inaccurate

  • Does adherence vary by treatment?

  • Where are the tanning salons?

Jan. 3, Jan. 10 & Jan. 17, 2018

Jan. 17, 2018:

  • How does the new tax reform law affect your practice?

  • HHS 2018 regulatory agenda includes sunscreen, sunlamps

  • Patients sue health insurer

  • New Advanced APM approved

Jan. 10, 2018:

  • Academy releases new NMSC clinical guidelines

  • Stem cell transplants for scleroderma patients may improve survival, quality of life

  • CMS launches new QPP data submission program

  • Drug approvals: FDA steps on the gas

  • AD drug receives FDA breakthrough therapy status

Jan. 3, 2018:

  • Anthem delays, changes modifier 25 cuts

  • FDA approves PD-1 inhibitor for melanoma

  • Spending on drugs slowed in 2016

  • Countdown to Medicare card transition begins

  • Health care discrepancies may exist for Native Americans

Additional Dermatology World Resources